Compare LSCC & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSCC | JAZZ |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 16.1B |
| IPO Year | 1994 | 2007 |
| Metric | LSCC | JAZZ |
|---|---|---|
| Price | $98.86 | $229.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 22 |
| Target Price | $156.19 | ★ $297.50 |
| AVG Volume (30 Days) | ★ 2.7M | 715.5K |
| Earning Date | 11-02-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.37 | 0.04 |
| Revenue | $385,961,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $89.72 | $12.68 |
| Revenue Next Year | $60.69 | $5.34 |
| P/E Ratio | ★ $299.89 | $5,907.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $65.53 | $156.95 |
| 52 Week High | $157.01 | $266.38 |
| Indicator | LSCC | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 48.42 |
| Support Level | $88.06 | $222.49 |
| Resistance Level | $101.49 | $244.93 |
| Average True Range (ATR) | 7.59 | 8.63 |
| MACD | 0.01 | 0.33 |
| Stochastic Oscillator | 12.33 | 36.41 |
Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.